Call 408.493.1800 | Fax 408.493.1801 | Toll Free 800.891.9699 (US Only) | Email: [email protected]

BioSim™ anti-Durvalumab (Human) ELISA Kit

A Sandwich ELISA kit for the Qualitative measurement of antibodies to Durvalumab in human serum or plasma samples

WARNING: This product can expose you to chemicals including TMB, which is [are] known to the State of California to cause birth defects or other reproductive harm.  For more information go to
Catalog #: E4926

Product Details

Cat # +Size E4926-100
Size 96 assays
Detection Method Absorbance (450 nm)
Species Reactivity Human
Applications This Sandwich ELISA kit is used for in vitro Qualitative determination of antibodies to Durvalumab in human serum and plasma samples
Features & Benefits • Assay Precision: Intra-Assay and Inter-Assay CV < 30%
• Cross Reactivity: Except for Durvalumab, there is no cross reaction with other therapeutic antibodies and native serum immunoglobins
• For in vitro Qualitative determination of antibodies to Durvalumab in human serum and plasma samples
Kit Components • Microtiter Plate
• Positive Control
• Negative Control
• Assay Buffer
• HRP-conjugate Probe
• TMB substrate (Avoid light)
• Stop Solution
• Wash buffer (20X)
• Plate sealers
Storage Conditions 4°C
Shipping Conditions Gel Pack
USAGE For Research Use Only! Not For Use in Humans.


Durvalumab is a human IgG1 monoclonal antibody that binds to and inhibits programmed cell death ligand 1 (PD-L1). PD-L1 is an important immune checkpoint molecule expressed on tumor cells and tumor-infiltrating immune cells. PD-L1 binds to its receptors PD-1 and B7.1 located on the surface of activated T cells and antigen-presenting cells and in turn suppresses cytotoxic T-cell activity, the proliferation of T-cells, and production of cytokines. The monoclonal antibody binds to PD-L1 and inhibits its anti-tumor immune response, and thus reduces tumor growth without causing antibody-dependent cellular cytotoxicity. The original antibody is approved to treat locally advanced or metastatic urothelial carcinoma and locally advanced unresectable non-small cell lung cancer (NSCLC). However, upon administration of the antibody, patients tend to develop an immune response that results in the formation of anti-Durvalumab antibodies, thus adversely affecting the therapeutic response to treatment. BioSim™ anti-Durvalumab ELISA kit qualitatively measures antibodies to Durvalumab in human serum or plasma samples. The kit is based on the Sandwich ELISA principle. Standards and samples (serum or plasma) are added to the microtiter plate coated with Durvalumab. After incubation, the wells are washed. The HRP conjugated probe is added and binds to the antibodies to Durvalumab that is captured by Durvalumab coated on the wells. Following incubation, wells are washed and the enzymatic activity is detected by the addition of TMB chromogen substrate. Finally, the reaction is terminated with an acidic stop solution. The color developed is proportional to the amount of antibodies to Durvalumab in the sample or standard. The qualitative test results can be evaluated using cut-off values.

Why buy BioVision Products?
Global Presence
Technical Support
BioVision aims to provide our customers innovative tools for accelerating drug discovery and biological research. BioVision offers >8,000 products including the most comprehensive array of assay kits for key targets in Metabolic pathways.
BioVision is committed to providing the highest quality products at a competitive price.
We have a broad network of global distributors who are ready to address your research needs and ensure fast delivery.
Our highly trained Technical Support team provides comprehensive product support and is dedicated to resolving your issues quickly and efficiently.